@toy59496@jordan_invests@asxpeasant $EIQ may have played this really well. PME deal, pre FDA = de risk + distribution +$250m additional market cap. Use higher valuation to raise $100m which gives them multi year runway. Still no FDA result known. BRAVO!
@toy59496@jordan_invests@asxpeasant $EIQ. I know we havenโt seen the full terms of the convertible, but gard to see how they default on a $10-$20m convertible when they have over $100m in the tin, which they will shortly.
@jordan_invests@toy59496@asxpeasant We havenโt seen the full terms of the convertible, but hard to see a default on a a $10m convertible with $100m+ in the tin!
@toy59496 2) this Ai tool in almost real-time, while ECG is being acquired, rates likelihood of disease (AS is HF or other). Overall detection rate significantly higher. Catching otherwise missed cases p, avoiding false +vs. more valves sold. Less readmission etc
@toy59496 Itโs a 80c v $2.80 in my mind. Think about as a decision assistant tool. The way it was pitched to me years ago was 1) currently Cardiologist sits down at night and goes through all the ECGโs that were taken that day and using their training/experience decides who has AS or HF
@toy59496 The alternative scenario is. Wait for FDA, stock pop to $1.80 from $1.20. 2 days later raise 20m at $1.50 from a range of long/medium and super short term money (some of which will be lent immediately). Compare this to the PME deal which includes distribution. I know which I like
@toy59496@nosynana1944 Feels to me that a labor green teal coalition postthe next federal election is the most likely. I hope I am wrong and some professional conservatives can team up with ON. Still too many labor lite wets in the libsโฆ
@toy59496 My understanding is that NEDA themselves โfollowed/accumulatec outcomesโ of the participants with the help of their physicians. I canโt vouch for the thorougness. when meeting the company in c2022 they said theyneeded to supp the data for African American genes which NEDA lacked